Q-VANT new state-of-the-art manufacturing facility is officially ready to start production!
This cutting-edge site leverages our proprietary Q-SAP technology, enabling us to purify millions of kilograms of sustainably sourced biomass for the production of QS-21 and other saponin adjuvants for vaccine manufacturers worldwide.
With over 4,000 m² of production space and 800 m² of laboratories and offices, this facility is built for industrial scale manufacturing. The next generation of saponins for vaccines and immunotherapies is now powered by a sustainable, secure, and high-volume production.
Our platform produces saponin adjuvants without cutting down a single tree, emancipating vaccines from the limited bark supply. Q-SAP technology is 1,000 folds more efficient than traditional methods.
This breakthrough ensures the reliable supply of these critical vaccine adjuvants, setting a new standard for sustainable manufacturing in the biomolecule industry.
